FierceBiotechOriginal article
{"a":[{"_":"After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration","$":{"href":"/biotech/after-missed-endpoint-gossamer-and-chiesi-pull-plug-pah-drug-collaboration","hreflang":"en"}}]}
PartnershipnegativeseralutinibNegative
AI Analysis
Summary
Gossamer Bio and Chiesi have terminated their collaboration on seralutinib for pulmonary arterial hypertension after the candidate missed its primary endpoint, ending a deal worth up to $486 million signed in 2024.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Collaboration ended after missed endpoint
Importance:7/10
Sentiment:
-0.80
partnership dissolutionmissed endpointPAHseralutinib
Related Companies
Read the original article
Published by FierceBiotech on July 27, 2026 10:05 AM